Filing Details

Accession Number:
0001062993-23-001384
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-01-25 17:25:25
Reporting Period:
2023-01-23
Accepted Time:
2023-01-25 17:25:25
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1621443 Zynerba Pharmaceuticals Inc. ZYNE () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1219866 Armando Anido C/O Zynerba Pharmaceuticals, Inc.
80 W. Lancaster Avenue, Suite 300
Devon PA 19333
Chairman & Chief Exec. Officer Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2023-01-23 35,453 $0.60 576,235 No 4 S Direct
Common Stock Acquisiton 2023-01-24 250,000 $0.00 826,235 No 4 A Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 A Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 26,595 Indirect See footnote
Common Stock 13,297 Indirect See footnote
Footnotes
  1. This transaction represents shares required to be sold by the Reporting Person to satisfy tax obligations and certain equity plan administrator fees in connection with the vesting of shares of restricted stock. This sale was mandated by the equity plan administrator and does not represent a discretionary trade by the Reporting Person.
  2. The restricted stock award will fully vest in two installments, subject to continued employment with the Company through the applicable vesting date: 1/3 of the restricted stock will vest on February 1, 2024; and 2/3 of the restricted stock will vest on February 1, 2025.
  3. TUA of Armando Anido and Nancy J. Anido Trusts are controlled by Armando Anido, who has voting and dispositive power with respect to shares held by the trusts.